Detalhe da pesquisa
1.
Responder rates with eptinezumab over 24 weeks in patients with prior preventive migraine treatment failures: post hoc analysis of the DELIVER randomized clinical trial.
Eur J Neurol
; 31(2): e16131, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37955557
2.
Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study.
Cephalalgia
; 43(5): 3331024231170807, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37125484
3.
Eptinezumab improved patient-reported outcomes and quality of life in patients with migraine and prior preventive treatment failures.
Eur J Neurol
; 30(4): 1089-1098, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36583633
4.
Efficacy and safety of eptinezumab in patients with chronic migraine and medication-overuse headache: a randomized, double-blind, placebo-controlled study.
BMC Neurol
; 23(1): 441, 2023 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38102535
5.
Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: extension of a randomized controlled trial.
J Headache Pain
; 24(1): 155, 2023 Nov 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37985968
6.
Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine.
Cephalalgia
; 42(10): 1005-1012, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35332807
7.
Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2.
Cephalalgia
; 42(8): 696-704, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35302389
8.
Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies.
BMC Neurol
; 22(1): 394, 2022 Oct 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36284281
9.
Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab.
BMC Neurol
; 22(1): 251, 2022 Jul 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35804294
10.
Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial.
BMC Neurol
; 22(1): 205, 2022 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35659622
11.
Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE-2 for research in migraine prevention.
Headache
; 62(6): 690-699, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35466430
12.
Eptinezumab for migraine prevention in patients 50 years or older.
Acta Neurol Scand
; 145(6): 698-705, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35218203
13.
Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects.
BMC Psychiatry
; 22(1): 548, 2022 08 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35962369
14.
Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study.
J Headache Pain
; 23(1): 91, 2022 Jul 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35902796
15.
Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study.
J Headache Pain
; 23(1): 153, 2022 Dec 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36460983
16.
Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study.
J Headache Pain
; 23(1): 22, 2022 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35130832
17.
Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial.
JAMA
; 325(23): 2348-2356, 2021 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34128999
18.
Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies.
J Headache Pain
; 22(1): 143, 2021 Nov 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34823467
19.
Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study.
CNS Spectr
; 24(6): 616-627, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30802419
20.
Correction: Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial.
BMC Neurol
; 23(1): 318, 2023 Sep 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37674117